×

Affimed Announces Third Quarter 2015 Financial Results and Corporate Update Conference Call

HEIDELBERG, Germany, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that on November 10, 2015, the Company will release its financial results for the quarter ended September 30, 2015. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, November 10, 2015 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 2648400.

Local - Amsterdam, the Netherlands: +31 (0) 20 716 8256
Local - Copenhagen, Denmark: +4538 48 75 13
Local – Frankfurt, Germany: +49 (0) 69 2222 10626
Local - Geneva, Switzerland: +41 (0) 22 567 5432
Local - London, U.K.: +44 (0) 20 3427 1911
Local - New York City, U.S.A.: +1 212 444 0481
Local - Paris, France: +33 (0) 1 70 48 01 66

An audio webcast of the conference call can be accessed in the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.

Contact:
Affimed N.V.
Caroline Stewart, Head IR & Communication
Phone: +1 347394 6793
E-Mail: IR@affimed.com or c.stewart@affimed.com

Media requests:
Anca Alexandru or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or
+49 163 613 3359
E-Mail: aalexandru@macbiocom.com

Source:Affimed Therapeutics